Cargando…
Inflammatory Burden and Immunomodulative Therapeutics of Cardiovascular Diseases
Phenotyping cardiovascular illness and recognising heterogeneities within are pivotal in the contemporary era. Besides traditional risk factors, accumulated evidence suggested that a high inflammatory burden has emerged as a key characteristic modulating both the pathogenesis and progression of card...
Autores principales: | Kao, Ting-Wei, Huang, Chin-Chou |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8775955/ https://www.ncbi.nlm.nih.gov/pubmed/35054989 http://dx.doi.org/10.3390/ijms23020804 |
Ejemplares similares
-
Cholinergic immunomodulation in inflammatory bowel diseases
por: Serafini, Michele A., et al.
Publicado: (2021) -
Recent Progress in Metabolic Syndrome Research and Therapeutics
por: Kao, Ting-Wei, et al.
Publicado: (2021) -
Repurposing traditional immunomodulators to target the inflammatory burden of atherosclerosis()
por: Fender, Anke C., et al.
Publicado: (2020) -
Immunomodulators as Therapeutic Agents in Mitigating the Progression of Parkinson’s Disease
por: Grimmig, Bethany, et al.
Publicado: (2016) -
Sulphamethazine derivatives as immunomodulating agents: New therapeutic strategies for inflammatory diseases
por: Siddiqui, Hina, et al.
Publicado: (2018)